Cellular Oncology

, Volume 37, Issue 1, pp 53–67 | Cite as

A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells

  • Yong Wu
  • Min Tang
  • Yuan Wu
  • Xinxian Weng
  • Lifang Yang
  • Wen Xu
  • Wie Yi
  • Jinghe Gao
  • Ann M. Bode
  • Zigang Dong
  • Ya Cao
Original Paper
First Online:
Accepted:

Abstract

Background

Stathmin, a microtubule associated protein (MAP), is an important molecular target for cancer therapy. Paclitaxel is one of the primary antitumor drugs targeting microtubules (MTs). We hypothesized that decreasing the expression level of Stathmin might improve the effectiveness of paclitaxel in the treatment of nasopharyngeal carcinoma (NPC).

Methods

NPC cell lines, CNE1-LMP1 and HNE2, and a CNE1-LMP1 tumor xenograft mouse model were used to test both in vitro and in vivo our siRNA-based Stathmin silencing strategy. The effects of Stathmin silencing on cell proliferation, apoptosis, and viability were investigated using MTT, AO/EB staining, TUNEL, caspase protein detection, and FCM assays. Cell migration and invasion were assayed using a Transwell assay. The combined effects of Stathmin silencing and paclitaxel were investigated using MTT, FCM, Western blot and indirect immunofluorescence assays. The effect of paclitaxel on Stathmin expression in NPC cells and, in addition, A375, MGC and HeLa cells was determined by RT-PCR and Western blotting.

Results

We found that siRNA-mediated silencing of Stathmin suppresses proliferation, induces apoptosis through the mitochondrial pathway, and causes G2/M-phase cell cycle arrest in the NPC cell lines CNE1-LMP1 and HNE2. Also, the migration and invasion of the respective NPC cells were found to be inhibited. In addition, we show that a combination of Stathmin silencing and paclitaxel is more effective than either agent alone in inhibiting proliferation and inducing apoptosis, cell cycle arrest, and MT polymerization. Furthermore, we found that Stathmin expression in the tumor cells is down-regulated by paclitaxel treatment.

Conclusion

siRNA-mediated silencing of Stathmin suppresses the proliferation, invasion and metastasis, and induces the apoptosis of NPC cells. Paclitaxel reduces the expression of Stathmin, and combining Stathmin silencing with paclitaxel treatment enhances MT polymerization. This combined strategy may provide a new approach for clinical NPC treatment.

Keywords

Stathmin siRNA Paclitaxel Microtubule Nasopharyngeal carcinoma 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was supported by the National Basic Research Program of China (973 Program) (2009CB521801 and 2011CB504305).

Supplementary material

13402_2013_163_MOESM1_ESM.doc (571 kb)
Fig. S1 Stathmin expression is silenced by si-stathmin in CNE1-LMP1 cells. CNE1-LMP1 cells were transfected with si-vector, si-Mock (as controls) or si-stathmin. si-Stathmin suppresses the expression of stathmin at the mRNA (a) and protein (b) levels in CNE1-LMP1 cells. The accompanying histogram (right) shows the quantitative luminosity values of each lane individually. Total RNA was extracted 24 h after transfection and was then amplified by RT-PCR. Expression of stathmin mRNA was detected with β-actin as an internal control. Meanwhile, total proteins were extracted 24 h after transfection and then examined by Western blot and α-tublin was used as a loading control. The data are shown as the mean ± S.D. of at least three independent experiments performed in duplication. Asterisks (*) indicate a significant decrease in expression of stathmin induced by si-stathmin. (DOC 571 kb)

References

  1. 1.
    J. Trovik, E. Wik, I.M. Stefansson, J. Marcickiewicz, S. Tingulstad, A.C. Staff, T.S. Njolstad, I. Vandenput, F. Amant, L.A. Akslen, H.B. Salvesen, Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clin Cancer Res 17, 3368–3377 (2011)PubMedCrossRefGoogle Scholar
  2. 2.
    A. Tradonsky, T. Rubin, R. Beck, B. Ring, R. Seitz, S. Mair, A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol 137, 918–930 (2012)PubMedCrossRefGoogle Scholar
  3. 3.
    M.T. Baquero, J.A. Hanna, V. Neumeister, H. Cheng, A.M. Molinaro, L.N. Harris, D.L. Rimm, Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 118, 4660–4669 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    F. Liu, Y.L. Sun, Y. Xu, L.S. Wang, X.H. Zhao, Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncol Rep 29, 419–424 (2013)PubMedGoogle Scholar
  5. 5.
    Y. Wang, Y. Kuramitsu, T. Ueno, N. Suzuki, S. Yoshino, N. Iizuka, X. Zhang, J. Akada, M. Oka, K. Nakamura, Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Oncol Rep 28, 1845–1850 (2012)PubMedGoogle Scholar
  6. 6.
    W. Kang, J.H. Tong, A.W. Chan, R.W. Lung, S.L. Chau, Q.W. Wong, N. Wong, J. Yu, A.S. Cheng, K.F. To, Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 7, e33919 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    H.T. Tan, W. Wu, Y.Z. Ng, X. Zhang, B. Yan, C.W. Ong, S. Tan, M. Salto-Tellez, S.C. Hooi, M.C. Chung, Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res 11, 1433–1445 (2012)PubMedCrossRefGoogle Scholar
  8. 8.
    L. Jiang, Y.K. Lai, J.F. Zhang, C.Y. Chan, G. Lu, M.C. Lin, M.L. He, J.C. Li, H.F. Kung, Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-beta-susceptible hepatocellular carcinoma cells. World J Gastroenterol 18, 2035–2042 (2012)PubMedCrossRefGoogle Scholar
  9. 9.
    Z. Xiao, G. Li, Y. Chen, M. Li, F. Peng, C. Li, F. Li, Y. Yu, Y. Ouyang, Z. Chen, Quantitative proteomic analysis of formalin-fixed and paraffin-embedded nasopharyngeal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem 58, 517–527 (2010)PubMedCrossRefGoogle Scholar
  10. 10.
    G. Yan, L. Li, Y. Tao, S. Liu, Y. Liu, W. Luo, Y. Wu, M. Tang, Z. Dong, Y. Cao, Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology. Proteomics 6, 1810–1821 (2006)PubMedCrossRefGoogle Scholar
  11. 11.
    X. Lin, S. Liu, X. Luo, X. Ma, L. Guo, L. Li, Z. Li, Y. Tao, Y. Cao, EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int J Cancer 124, 1020–1027 (2009)PubMedCrossRefGoogle Scholar
  12. 12.
    X. Lin, M. Tang, Y. Tao, L. Li, S. Liu, L. Guo, Z. Li, X. Ma, J. Xu, Y. Cao, Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle. Cancer Sci 103, 993–999 (2012)PubMedCrossRefGoogle Scholar
  13. 13.
    B. Belletti, M.S. Nicoloso, M. Schiappacassi, S. Berton, F. Lovat, K. Wolf, V. Canzonieri, S. D’Andrea, A. Zucchetto, P. Friedl, A. Colombatti, G. Baldassarre, Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19, 2003–2013 (2008)PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    X.L. Meng, D. Su, L. Wang, Y. Gao, Y.J. Hu, H.J. Yang, S.N. Xie, Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. Genet Test Mol Biomarkers 16, 689–694 (2012)PubMedCrossRefGoogle Scholar
  15. 15.
    F. Ge, C.L. Xiao, L.J. Bi, S.C. Tao, S. Xiong, X.F. Yin, L.P. Li, C.H. Lu, H.T. Jia, Q.Y. He, Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One 5, e13095 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Y.J. Cui, S.H. Guan, L.X. Feng, X.Y. Song, C. Ma, C.R. Cheng, W.B. Wang, W.Y. Wu, Q.X. Yue, X. Liu, D.A. Guo, Cytotoxicity of 9,11-dehydroergosterol peroxide isolated from Ganoderma lucidum and its target-related proteins. Nat Prod Commun 5, 1183–1186 (2010)PubMedGoogle Scholar
  17. 17.
    L. Hao, P. Xie, H. Li, G. Li, Q. Xiong, Q. Wang, T. Qiu, Y. Liu, Transcriptional alteration of cytoskeletal genes induced by microcystins in three organs of rats. Toxicon 55, 1378–1386 (2010)PubMedCrossRefGoogle Scholar
  18. 18.
    X. Shi, D. Wang, K. Ding, Z. Lu, Y. Jin, J. Zhang, J. Pan, GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther 9, 640–650 (2010)PubMedCrossRefGoogle Scholar
  19. 19.
    X. Wang, J.H. Ren, F. Lin, J.X. Wei, M. Long, L. Yan, H.Z. Zhang, Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther 10, 632–643 (2010)PubMedCrossRefGoogle Scholar
  20. 20.
    S.J. Mistry, C.J. Benham, G.F. Atweh, Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 11, 41–49 (2001)PubMedCrossRefGoogle Scholar
  21. 21.
    A.P. Phadke, C.M. Jay, Z. Wang, S. Chen, S. Liu, C. Haddock, P. Kumar, B.O. Pappen, D.D. Rao, N.S. Templeton, E.Q. Daniels, C. Webb, D. Monsma, S. Scott, D. Dylewski, H.B. Frieboes, F.C. Brunicardi, N. Senzer, P.B. Maples, J. Nemunaitis, A.W. Tong, In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol 30, 715–726 (2011)PubMedCrossRefGoogle Scholar
  22. 22.
    D.D. Rao, P.B. Maples, N. Senzer, P. Kumar, Z. Wang, B.O. Pappen, Y. Yu, C. Haddock, C. Jay, A.P. Phadke, S. Chen, J. Kuhn, D. Dylewski, S. Scott, D. Monsma, C. Webb, A. Tong, D. Shanahan, J. Nemunaitis, Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther 17, 780–791 (2010)PubMedCrossRefGoogle Scholar
  23. 23.
    R. Wang, K. Dong, F. Lin, X. Wang, P. Gao, S.H. Wei, S.Y. Cheng, H.Z. Zhang, Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med 13, 567–575 (2007)PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    E. Alli, J.M. Yang, J.M. Ford, W.N. Hait, Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 71, 1233–1240 (2007)PubMedCrossRefGoogle Scholar
  25. 25.
    S.Y. Gu, W.P. Tang, Y. Zeng, E.W. Zhao, W.H. Deng, K. Li, An epithelial cell line established from poorly differentiated nasopharyngeal carcinoma (in Chinese). Chin. J. Cancer 2, 70–72 (1983)Google Scholar
  26. 26.
    A. Albini, Y. Iwamoto, H.K. Kleinman, G.R. Martin, S.A. Aaronson, J.M. Kozlowski, R.N. McEwan, A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47, 3239–3245 (1987)PubMedGoogle Scholar
  27. 27.
    S.Z. Chen, M. Jiang, Y.S. Zhen, HERG K + channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol 56, 212–220 (2005)PubMedCrossRefGoogle Scholar
  28. 28.
    P. Zheng, Y.X. Liu, L. Chen, X.H. Liu, Z.Q. Xiao, L. Zhao, G.Q. Li, J. Zhou, Y.Q. Ding, J.M. Li, Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 9, 4897–4905 (2010)PubMedCrossRefGoogle Scholar
  29. 29.
    B. Belletti, I. Pellizzari, S. Berton, L. Fabris, K. Wolf, F. Lovat, M. Schiappacassi, S. D’Andrea, M.S. Nicoloso, S. Lovisa, M. Sonego, P. Defilippi, A. Vecchione, A. Colombatti, P. Friedl, G. Baldassarre, p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 30, 2229–2240 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    C. Iancu, S.J. Mistry, S. Arkin, G.F. Atweh, Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 60, 3537–3541 (2000)PubMedGoogle Scholar
  31. 31.
    R. Balachandran, M.J. Welsh, B.W. Day, Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 22, 8924–8930 (2003)PubMedCrossRefGoogle Scholar
  32. 32.
    F. Gong, X. Peng, Z. Zeng, M. Yu, Y. Zhao, A. Tong, Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol Cell Biochem 348, 141–147 (2011)PubMedCrossRefGoogle Scholar
  33. 33.
    M. Balasubramani, C. Nakao, G.T. Uechi, J. Cardamone, K. Kamath, K.L. Leslie, R. Balachandran, L. Wilson, B.W. Day, M.A. Jordan, Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis. Mutat Res 722, 154–164 (2011)PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    J.R. Carr, H.J. Park, Z. Wang, M.M. Kiefer, P. Raychaudhuri, FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70, 5054–5063 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    S. Hasegawa, N. Hirashima, M. Nakanishi, Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes. Gene Ther 8, 1669–1673 (2001)PubMedCrossRefGoogle Scholar
  36. 36.
    R.R. Nair, J.R. Rodgers, L.A. Schwarz, Enhancement of transgene expression by combining glucocorticoids and anti-mitotic agents during transient transfection using DNA-cationic liposomes. Mol Ther 5, 455–462 (2002)PubMedCrossRefGoogle Scholar
  37. 37.
    L.A. Martello, P. Verdier-Pinard, H.J. Shen, L. He, K. Torres, G.A. Orr, S.B. Horwitz, Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 63, 1207–1213 (2003)PubMedGoogle Scholar
  38. 38.
    J. Okano, A.K. Rustgi, Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem. 276, 19555–19564 (2001)PubMedCrossRefGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2013

Authors and Affiliations

  • Yong Wu
    • 1
    • 2
    • 3
    • 4
  • Min Tang
    • 1
    • 3
    • 4
  • Yuan Wu
    • 1
    • 2
    • 3
    • 4
  • Xinxian Weng
    • 1
    • 3
    • 4
  • Lifang Yang
    • 1
    • 3
    • 4
  • Wen Xu
    • 1
    • 2
    • 3
    • 4
  • Wie Yi
    • 1
    • 3
    • 4
  • Jinghe Gao
    • 1
    • 3
    • 4
  • Ann M. Bode
    • 5
  • Zigang Dong
    • 5
  • Ya Cao
    • 1
    • 3
    • 4
  1. 1.Cancer Research Institute, Xiangya School of MedicineCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Department of Medicine Clinical LaboratoryThe Third Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China
  3. 3.Carcinogenesis and Invasion Key Laboratory of Education Ministry of ChinaCentral South UniversityChangshaPeople’s Republic of China
  4. 4.Molecular Image Research CenterCentral South UniversityChangshaPeople’s Republic of China
  5. 5.The Hormel InstituteUniversity of MinnesotaAustinUSA

Personalised recommendations